Edit Reading

Back to List

Basic Information

Title

Please enter a title.

URL

Please enter a valid URL.

Date

カテゴリID

画像ファイル名

単語数（空欄の場合は本文から自動計算）空欄の場合は本文から自動計算されます。本文が空欄の場合は既存の値が保持されます。

統計情報

現在の単語数: 144語

読了回数: 0回

作成日: 2022/11/22 07:18

更新日: 2025/12/09 11:19

本文

Japan&#039;s health ministry is to convene a meeting of experts on Tuesday to discuss whether to approve an oral coronavirus drug developed by Japanese pharmaceutical company Shionogi. If approved, it would be the first domestically developed oral drug for patients with mild COVID-19 symptoms.
                
The move comes after a ministry council decided in July to continue deliberating Shionogi&#039;s application for emergency authorization of the drug, Xocova, citing a lack of data. The company filed the application in February.
                
During Tuesday&#039;s meeting, experts will look into new clinical data Shionogi has submitted to prove Xocova&#039;s efficacy. The experts will also assess its safety.
                
Two other oral medications for mild COVID-19, both developed by foreign pharmaceutical firms, have been authorized for use in Japan. They are intended for use in patients at high risk of developing severe symptoms. Shionogi&#039;s Xocova is also available to low-risk patients.

メモ

メモ・感想

キャンセル

Edit Reading

Basic Information

統計情報

本文

メモ

Send Report